Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 9/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 9/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5954581 | 0.86 | CSNK1D (0.40) | CSNK1DCSNK1EKDRMAP4K1 | |
| SCHEMBL5954568 | 0.85 | KDR (0.42) | LRRK2CSNK1DCSNK1EKDRMAP4K1 | |
| SCHEMBL5955345 | 0.84 | CSNK1D (0.41) | CSNK1DCSNK1EKDR | |
| SCHEMBL5955517 | 0.84 | CSNK1D (0.43) | CSNK1DCSNK1EKDR | |
| SCHEMBL251717 | 0.83 | CSNK1D (0.41) | LRRK2CSNK1DCSNK1EKDR | |
| SCHEMBL2747152 | 0.83 | CSNK1D (0.41) | CSNK1DCSNK1EKDRMAP4K1 | |
| SCHEMBL3397327 | 0.83 | KDR (0.44) | CSNK1DCSNK1EKDR | |
| SCHEMBL5954869 | 0.83 | KDR (0.48) | CSNK1DCSNK1EKDR | |
| SCHEMBL5954598 | 0.83 | PIK3CA (0.45) | CSNK1DCSNK1EKDR | |
| SCHEMBL5955350 | 0.82 | ADORA2A (0.42) | ADORA2BCSNK1DCSNK1EKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063054-A1 | cMET INHIBITORS | CEPT1, LCAT, GNMT | ABL1 114/4885LRRK2 2105/4885ADORA2B 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.